Cisplatin first entered oncology in 1978 when it was approved for the treatment of testicular cancer. Subsequently, intravenous platinum compounds such as cisplatin, carboplatin and oxaliplatin have become some of the most widely used drugs in oncology today.
Satraplatin is a fourth-generation orally bioavailable precision platinum compound with activity against cisplatin-sensitive and cisplatin-resistant tumours, and a milder toxicity profile. It benefits from a unique oral administration with convenient 5-day schedule and optimal pharmacokinetics, has very low nephrotoxicity or neurotoxicity, and has targeted cellular activity.
